FDA staff flag no major concerns for Grail's multi-cancer test ahead of advisory committee

FDA staff have completed a review of Grail's multi-cancer early detection test and reported no major concerns.

The assessment comes as the test approaches a scheduled advisory committee meeting, where further discussion and evaluation are expected.

Regulatory officials indicated that the current data package appears sufficient for the next stage of review, though final decisions will depend on the committee's deliberations.

Separately, the Trump administration is reported to be drafting an order aimed at increasing oversight of the agency's regulatory processes, which could affect future reviews.